Titanium(IV)-based anticancer complexes were the first to enter clinical trials after platinum compounds. [1] In particular, budotitane ([(bzac) 2 Ti(OEt) 2 ]; bzac = benzoylacetonate) and titanocene dichloride ([Cp 2 TiCl 2 ]; Cp = cyclopentadienyl) demonstrated high antitumor activity with reduced toxicity toward a range of cancer cells; however, use of these complexes, which both bear two labile ligands, was limited by their instability in water. [2] Therefore, mechanistic aspects remained unresolved, including the nature of the active species and its identification from the multiple hydrolysis products that were formed. We have recently introduced cytotoxic salan-Ti IV complexes, [3] which are: a) substantially more hydrolytically stable than known Ti IV complexes, and b) markedly more active than [(bzac) 2 Ti(OiPr) 2 ], [Cp 2 TiCl 2 ], and cis-platin toward a variety of cancer-derived cell lines. Structure-activity-relationship studies based on both salan [3a,b,e-h, 4a,b] and labile ligand [3g, 4c,d] variations revealed that reduced steric bulk is favored for cytotoxicity. Additionally, all cytotoxic complexes slowly gave defined oxo-bridged polynuclear hydrolysis products. [3b,e-g] Particularly, N-methylated complexes produced well-defined trinuclear clusters, [3f,g] which were stable for weeks in water. Several observations indicated that the hydrolysis products play a meaningful role in the cytotoxicity mechanism; [3] nevertheless, direct measurements on the isolated clusters showed no activity. [3f,g] Herein we address the hypothesis that cellular penetration, which is size-dependent, and/or impaired solubility were limiting factors, and that labile ligands may actually not be required for cytotoxicity of Ti IV complexes, unlike for cisplatin. [6] This paper presents the high activity of a hydrolysis product and other particularly resistant Ti IV complexes, the